Document Detail

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
MedLine Citation:
PMID:  23169319     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: There is a need for comparative studies to provide evidence-based treatment guidance for biologic agents in rheumatoid arthritis (RA). Therefore, this study was undertaken as the first head-to-head comparison of subcutaneous (SC) abatacept and SC adalimumab, both administered along with background methotrexate (MTX), for the treatment of RA.
METHODS: Patients with active RA who were naive to treatment with biologic agents and had an inadequate response to MTX were randomly assigned to receive 125 mg SC abatacept weekly or 40 mg SC adalimumab biweekly, both given in combination with MTX, in a 2-year study. The primary end point was treatment noninferiority, assessed according to the American College of Rheumatology 20% improvement response (ACR20) at 1 year.
RESULTS: Of the 646 patients who were randomized and treated, 86.2% receiving SC abatacept and 82% receiving SC adalimumab completed 12 months of treatment. At 1 year, 64.8% of patients in the SC abatacept group and 63.4% in the SC adalimumab group demonstrated an ACR20 response; the estimated difference between groups was 1.8% (95% confidence interval -5.6%, 9.2%), thus demonstrating the noninferiority of abatacept compared to adalimumab. All efficacy measures showed similar results and kinetics of response between treatments. The rate of radiographic nonprogression (defined as a total modified Sharp/van der Heijde score [SHS] less than or equal to the smallest detectable change) was 84.8% for SC abatacept-treated patients and 88.6% for SC adalimumab-treated patients, while the mean change from baseline in the total SHS was 0.58 and 0.38, respectively. In the SC abatacept and SC adalimumab groups, the incidence of serious adverse events (SAEs) was 10.1% and 9.1%, respectively, and the rate of serious infections was 2.2% and 2.7%, respectively. In patients treated with SC abatacept, the frequency of discontinuations due to AEs was 3.5% and discontinuations due to SAEs was 1.3%, while in patients treated with SC adalimumab, the frequencies were 6.1% and 3%, respectively. Injection site reactions occurred in 3.8% of patients receiving SC abatacept compared to 9.1% of patients receiving SC adalimumab (P=0.006).
CONCLUSION: The results demonstrate that SC abatacept and SC adalimumab have comparable efficacy in patients with RA, as shown by similar kinetics of response and comparable inhibition of radiographic progression over 1 year of treatment. The safety was generally similar, other than the occurrence of significantly more local injection site reactions in patients treated with SC adalimumab.
Michael E Weinblatt; Michael Schiff; Robert Valente; Désirée van der Heijde; Gustavo Citera; Cathy Zhao; Michael Maldonado; Roy Fleischmann
Related Documents :
20306199 - Rare complication after vac-therapy in the treatment of deep sore ulcers in a paraplegi...
23539709 - The long-term clinical outcome after pelvic ring injuries.
23952719 - Symptomatology and functional outcome in mild traumatic brain injury: results from the ...
15243559 - Predictors of wound complications after laryngectomy: a study of over 2000 patients.
7748749 - The effect of ketanserin on healing of fresh surgical wounds.
23595509 - Mortality and major morbidity after tonsillectomy: etiologic factors and strategies for...
24654699 - Phaco-trabeculectomy in controlled, advanced, open-angle glaucoma and cataract: paralle...
22387399 - Botulinum toxin a in the treatment of spasticity - an open label study.
19149979 - Risk factors of preseptal and orbital cellulitis.
Publication Detail:
Type:  Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Arthritis and rheumatism     Volume:  65     ISSN:  1529-0131     ISO Abbreviation:  Arthritis Rheum.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-02     Completed Date:  2013-03-17     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  0370605     Medline TA:  Arthritis Rheum     Country:  United States    
Other Details:
Languages:  eng     Pagination:  28-38     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013 by the American College of Rheumatology.
Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal, Humanized / administration & dosage,  adverse effects,  therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Antirheumatic Agents / administration & dosage,  adverse effects,  therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Immunoconjugates / administration & dosage,  adverse effects,  therapeutic use*
Methotrexate / administration & dosage,  adverse effects,  therapeutic use*
Middle Aged
Prospective Studies
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Immunoconjugates; 59-05-2/Methotrexate; 7D0YB67S97/abatacept; FYS6T7F842/adalimumab
Comment In:
Nat Rev Rheumatol. 2013 Jan;9(1):1   [PMID:  23229451 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome i...
Next Document:  Long-term follow-up of DDH patients who underwent open reduction without a postoperative cast.